ClinicalTrials.gg
CompletedNCT01185288MUSICAUpdated Mar 18, 2014Results posted

A Study to Determine the Effect of Methotrexate (MTX) Dose on Clinical Outcome and Ultrasonographic Signs in Subjects With Moderately to Severely Active Rheumatoid Arthritis (RA) Treated With Adalimumab (MUSICA)

A Phase 4 interventional study of Adalimumab and Methotrexate in Rheumatoid Arthritis, sponsored by AbbVie (prior sponsor, Abbott). Completed at 49 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-03-18.

Sponsored by AbbVie (prior sponsor, Abbott) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
309
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 87 studies testing adalimumab in Arthritis, Rheumatoid — 4 open to participants now, 6 under way, 2 of them phase 3. Adalimumab · Arthritis, Rheumatoid.

Enrollment
29th of 87
309 · median 160
Started
2010
with 3 others
Phase 4
33 of 87
1 open now
Registered
37th of 87
by date
Lead sponsor
7 of 87
AbbVie (prior sponsor, Abbott)

Among the 87 studies testing adalimumab in Arthritis, Rheumatoid, this one is the 29th largest by enrollment, is one of 4 that started in 2010, is one of 33 in phase 4, and was the 37th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

4 of the 87 studies testing adalimumab in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About adalimumab

Adalimumab: first FDA approval 2002 (HUMIRA), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 87 studies testing adalimumab in Arthritis, Rheumatoid, or all of them as a file.
02

Study summary

This study will investigate the efficacy of both low and high doses of methotrexate (MTX) in combination with open-label adalimumab (ADA) in patients who have had an inadequate response to high dose of MTX. The study will also evaluate the pharmacokinetics and safety of the two regimens of MTX in combination with ADA in participants with rheumatoid arthritis (RA).

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult subjects with moderately to severely active rheumatoid arthritis
  • Subjects must have a DAS28(CRP) (Disease Activity Score using C-Reactive Protein) greater than or equal to 3.2 at baseline (there is no minimum CRP score required to qualify)
  • Subjects must have at least 5/68 tender joints plus 5/66 swollen joints assessed at screening or baseline
  • Subject must treated with and MTX (methotrexate) dose (oral and/or injectable) of 15 mg or more per week (no upper limit on dose) for at least 12 weeks prior to screening
  • Subject is either biologic-naïve or has only one prior biologic disease-modifying antirheumatic drug (i.e. abatacept, anakinra, certolizumab, etanercept, golimumab, infliximab, or tocilizumab)

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to adalimumab (Humira), rituximab (Rituxan), natalizumab (Tysabri), efalizumab (Raptiva)
  • Subject has been treated with intra-articular or parenteral administration of within 4 weeks of screening
  • Subject has diagnosis or history of gout or pseudogout
  • Subject has undergone joint surgery within 12 weeks of screening (at joints to be assessed by ultrasound)
  • Subject has history of chronic arthritis diagnosed before age 16 years
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
309 participants (actual)

Study arms

  • Experimental
    Adalimumab + Low Dose Methotrexate

    Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, low dose methotrexate (7.5 mg orally once weekly).

    Biological: Adalimumab · Drug: Methotrexate

  • Active comparator
    Adalimumab + High Dose Methotrexate

    Open-label adalimumab (40 mg subcutaneous every other week) plus blinded, high dose methotrexate (20 mg orally once weekly).

    Biological: Adalimumab · Drug: Methotrexate

Interventions

  • BiologicalAdalimumab

    Adalimumab in pre-filled syringes

    Also known as: ABT-D2E7, Humira

  • Methotrexate capsule

06

What researchers measure

Primary outcomes

  1. Disease Activity Score for 28 Joints Based on C-reactive Protein (DAS28[CRP]) at Week 24

    The DAS28(CRP) score includes 28 tender joint counts, 28 swollen joint counts, C-reactive protein, and participant's global assessment of disease activity. Scores on the DAS28(CRP) range from 0 to 10. A DAS28(CRP) score ≥ 5.1 indicates high disease activity, and a DAS28(CRP) score \< 2.6 indicates clinical remission. Least squares means and 95% CI were from 2-way ANCOVA model with effects for baseline DAS28(CRP) value, treatment group, and prior methotrexate dose group.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With Power Doppler Ultrasound (PD U/S) Score for Synovial Vascularity Improvement by 30% at Week 24

    PD U/S assessed the severity of synovial inflammation in both hands (bilateral wrists, metacarpophalangeal joints 2, 3, 5, and metatarsophalangeal joint 5). Bilateral images based on dorsal midline imaging of the wrist, dorsal and volar imaging of metacarpophalangeal joints, and dorsal imaging alone of metatarsophalangeal joints are scored using a 4-grade scale: grade 0 or normal = normal joint (no Doppler signal); grade 1 or mild = mild synovitis (≤ 3 isolated signals); grade 2 or moderate = moderate synovitis (\> 3 isolated signals or a confluent signal in \< 50% of synovial area); grade 3 or marked = marked synovitis (signals in ≥ 50% of the synovial area). Each image is rated 0 to 3, for a total possible score ranging from 0 to 48 (16\*0, 16\*3) for 2 hands. Higher grade/score=more severe disease. Change = week 24 score - baseline score.

    Time frame: Baseline, 24 weeks

  2. Percentage of Participants With American College of Rheumatology 50% (ACR50) Criteria Response at Week 24

    Response, as defined by ACR50 criteria at week 24. A participant is a responder if the following 3 criteria for improvement from baseline are met: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant assessment of pain, disability index of the health assessment questionnaire, and acute phase reactant value (C-reactive protein).

    Time frame: Baseline, 24 weeks

  3. Percentage of Participants With American College of Rheumatology 70% (ACR70) Criteria Response at Week 24

    Response, as defined by ACR70 criteria at week 24. A participant is a responder if the following 3 criteria for improvement from baseline are met: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant assessment of pain, disability index of the health assessment questionnaire, and acute phase reactant value (C-reactive protein).

    Time frame: Baseline, 24 weeks

  4. Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤ -0.22 at Week 24

    The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0), with some difficulty (1), with much difficulty (2), and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (no disability) to 3 (very severe, high dependency disability). The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from baseline of ≤ -0.22. Normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from baseline in the overall score indicates improvement.

    Time frame: Baseline, 24 weeks

  5. Percent Change From Baseline in Medical Outcomes Study Version II (MOS) Sleep Problem Index 9 at Week 24

    The least squares mean percentage change in MOS Sleep Problem Index 9 from baseline to week 24. The MOS Sleep Problem Index 9 consists of 9 questions to assess sleep, including how long it takes the participant to fall asleep (1=0 to 15 minutes, to 5=more than 60 minutes); and aspects of related to quality of sleep, including how often the participant felt that the sleep was not quiet, felt rested upon waking, awakened short of breath or with a headache, felt drowsy during the day, had trouble falling sleep, how often were awaken, had trouble staying awake during the day, and got needed amount of sleep (1=all the time; 5=none of the time). Least squares means and 95% CI were from 2-way ANCOVA model with effects for baseline MOS Sleep Problem Index value, treatment group, and prior methotrexate dose group.

    Time frame: Baseline, 24 weeks

Other outcomes

  1. Serum Adalimumab Trough Concentrations at Week 24

    Serum trough concentrations of adalimumab assessed at week 24 (24 weeks after the 1st dose).

    Time frame: Week 24

07

Results

Posted Mar 18, 2014

Participant flow

Participant flow — Overall Study
MilestoneAdalimumab + Low Dose MethotrexateAdalimumab + High Dose Methotrexate
Started154155
Completed135139
Not completed1916
Withdrew: Adverse event76
Withdrew: Withdrawal by subject64
Withdrew: Lost to follow-up25
Withdrew: Lack of efficacy20
Withdrew: Investigator discretion10
Withdrew: Did not meet inclusion criteria10
Withdrew: Noncompliance01

Outcome measures

PrimaryDisease Activity Score for 28 Joints Based on C-reactive Protein (DAS28[CRP]) at Week 24

The DAS28(CRP) score includes 28 tender joint counts, 28 swollen joint counts, C-reactive protein, and participant's global assessment of disease activity. Scores on the DAS28(CRP) range from 0 to 10. A DAS28(CRP) score ≥ 5.1 indicates high disease activity, and a DAS28(CRP) score \< 2.6 indicates clinical remission. Least squares means and 95% CI were from 2-way ANCOVA model with effects for baseline DAS28(CRP) value, treatment group, and prior methotrexate dose group.

Time frame:
Week 24
Reported as:
Least squares mean · scores on a scale
Disease Activity Score for 28 Joints Based on C-reactive Protein (DAS28[CRP]) at Week 24
scores on a scaleAdalimumab + Low Dose MethotrexateAdalimumab + High Dose Methotrexate
Disease Activity Score for 28 Joints Based on C-reactive Protein (DAS28[CRP]) at Week 244.11 (3.88 to 4.34)3.75 (3.52 to 3.97)
SecondaryPercentage of Participants With Power Doppler Ultrasound (PD U/S) Score for Synovial Vascularity Improvement by 30% at Week 24

PD U/S assessed the severity of synovial inflammation in both hands (bilateral wrists, metacarpophalangeal joints 2, 3, 5, and metatarsophalangeal joint 5). Bilateral images based on dorsal midline imaging of the wrist, dorsal and volar imaging of metacarpophalangeal joints, and dorsal imaging alone of metatarsophalangeal joints are scored using a 4-grade scale: grade 0 or normal = normal joint (no Doppler signal); grade 1 or mild = mild synovitis (≤ 3 isolated signals); grade 2 or moderate = moderate synovitis (\> 3 isolated signals or a confluent signal in \< 50% of synovial area); grade 3 or marked = marked synovitis (signals in ≥ 50% of the synovial area). Each image is rated 0 to 3, for a total possible score ranging from 0 to 48 (16\*0, 16\*3) for 2 hands. Higher grade/score=more severe disease. Change = week 24 score - baseline score.

Time frame:
Baseline, 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With Power Doppler Ultrasound (PD U/S) Score for Synovial Vascularity Improvement by 30% at Week 24
percentage of participantsAdalimumab + Low Dose MethotrexateAdalimumab + High Dose Methotrexate
Percentage of Participants With Power Doppler Ultrasound (PD U/S) Score for Synovial Vascularity Improvement by 30% at Week 2445.4552.38
SecondaryPercentage of Participants With American College of Rheumatology 50% (ACR50) Criteria Response at Week 24

Response, as defined by ACR50 criteria at week 24. A participant is a responder if the following 3 criteria for improvement from baseline are met: ≥ 50% improvement in tender joint count; ≥ 50% improvement in swollen joint count; and ≥ 50% improvement in at least 3 of the 5 following parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant assessment of pain, disability index of the health assessment questionnaire, and acute phase reactant value (C-reactive protein).

Time frame:
Baseline, 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology 50% (ACR50) Criteria Response at Week 24
percentage of participantsAdalimumab + Low Dose MethotrexateAdalimumab + High Dose Methotrexate
Percentage of Participants With American College of Rheumatology 50% (ACR50) Criteria Response at Week 2429.8037.66
SecondaryPercentage of Participants With American College of Rheumatology 70% (ACR70) Criteria Response at Week 24

Response, as defined by ACR70 criteria at week 24. A participant is a responder if the following 3 criteria for improvement from baseline are met: ≥ 70% improvement in tender joint count; ≥ 70% improvement in swollen joint count; and ≥ 70% improvement in at least 3 of the 5 following parameters: physician global assessment of disease activity, participant global assessment of disease activity, participant assessment of pain, disability index of the health assessment questionnaire, and acute phase reactant value (C-reactive protein).

Time frame:
Baseline, 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With American College of Rheumatology 70% (ACR70) Criteria Response at Week 24
percentage of participantsAdalimumab + Low Dose MethotrexateAdalimumab + High Dose Methotrexate
Percentage of Participants With American College of Rheumatology 70% (ACR70) Criteria Response at Week 2413.2520.13
SecondaryPercentage of Participants With a Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤ -0.22 at Week 24

The HAQ-DI is a patient-reported questionnaire specific for rheumatoid arthritis. It consists of 20 questions referring to 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and daily activities. Participants assessed their ability to do each task over the past week using the following response categories: without any difficulty (0), with some difficulty (1), with much difficulty (2), and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (no disability) to 3 (very severe, high dependency disability). The minimal clinically important difference (MCID) defined for the HAQ-DI is a change from baseline of ≤ -0.22. Normal physical function is defined by HAQ-DI score of \< 0.5. Negative change from baseline in the overall score indicates improvement.

Time frame:
Baseline, 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤ -0.22 at Week 24
percentage of participantsAdalimumab + Low Dose MethotrexateAdalimumab + High Dose Methotrexate
Percentage of Participants With a Change From Baseline in Health Assessment Questionnaire - Disability Index (HAQ-DI) ≤ -0.22 at Week 2463.5865.58
SecondaryPercent Change From Baseline in Medical Outcomes Study Version II (MOS) Sleep Problem Index 9 at Week 24

The least squares mean percentage change in MOS Sleep Problem Index 9 from baseline to week 24. The MOS Sleep Problem Index 9 consists of 9 questions to assess sleep, including how long it takes the participant to fall asleep (1=0 to 15 minutes, to 5=more than 60 minutes); and aspects of related to quality of sleep, including how often the participant felt that the sleep was not quiet, felt rested upon waking, awakened short of breath or with a headache, felt drowsy during the day, had trouble falling sleep, how often were awaken, had trouble staying awake during the day, and got needed amount of sleep (1=all the time; 5=none of the time). Least squares means and 95% CI were from 2-way ANCOVA model with effects for baseline MOS Sleep Problem Index value, treatment group, and prior methotrexate dose group.

Time frame:
Baseline, 24 weeks
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Medical Outcomes Study Version II (MOS) Sleep Problem Index 9 at Week 24
percent changeAdalimumab + Low Dose MethotrexateAdalimumab + High Dose Methotrexate
Percent Change From Baseline in Medical Outcomes Study Version II (MOS) Sleep Problem Index 9 at Week 24-15.42 (-25.36 to -5.49)-17.27 (-27.95 to -7.58)
Other pre-specifiedSerum Adalimumab Trough Concentrations at Week 24

Serum trough concentrations of adalimumab assessed at week 24 (24 weeks after the 1st dose).

Time frame:
Week 24
Reported as:
Mean · µg/mL
Serum Adalimumab Trough Concentrations at Week 24
µg/mLAdalimumab + Low Dose MethotrexateAdalimumab + High Dose Methotrexate
Serum Adalimumab Trough Concentrations at Week 247.1 ± 6.28.6 ± 5.2

Adverse events

Collected over AEs that occurred from the time of study drug administration until 70 days after last dose (total 34 weeks). SAEs were to be collected from the time that informed consent was obtained until 70 days after last dose (total 41 weeks).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Adalimumab + Low Dose Methotrexate—6/154 (3.9%)57/154 (37%)
Adalimumab + High Dose Methotrexate—11/155 (7.1%)48/155 (31%)
Most frequent serious events
Showing 10 of 19
Most frequent serious events
EventAdalimumab + Low Dose MethotrexateAdalimumab + High Dose Methotrexate
ANAEMIABlood and lymphatic system disorders1/1540/155
ACUTE MYOCARDIAL INFARCTIONCardiac disorders1/1540/155
COLITIS ISCHAEMICGastrointestinal disorders1/1540/155
BILE DUCT CANCERNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/1540/155
TRANSIENT ISCHAEMIC ATTACKNervous system disorders1/1540/155
RAYNAUD'S PHENOMENONVascular disorders1/1540/155
COLITISGastrointestinal disorders0/1541/155
NON-CARDIAC CHEST PAINGeneral disorders0/1541/155
ABSCESS SOFT TISSUEInfections and infestations0/1541/155
CELLULITISInfections and infestations0/1541/155
Most frequent other events
Most frequent other events
EventAdalimumab + Low Dose MethotrexateAdalimumab + High Dose Methotrexate
NAUSEAGastrointestinal disorders15/15416/155
FATIGUEGeneral disorders14/1544/155
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations14/15412/155
ALOPECIASkin and subcutaneous tissue disorders11/1544/155
URINARY TRACT INFECTIONInfections and infestations8/15411/155
DIZZINESSNervous system disorders10/1549/155
HEADACHENervous system disorders10/1549/155
DIARRHOEAGastrointestinal disorders9/1546/155
RHEUMATOID ARTHRITISMusculoskeletal and connective tissue disorders9/1545/155

Baseline characteristics

Age, Continuous
Age, Continuous(years)Adalimumab + Low Dose MethotrexateAdalimumab + High Dose MethotrexateTotal
Mean55.1 ± 13.1154.5 ± 11.0954.8 ± 12.12
Sex: Female, Male
Sex: Female, Male(Participants)Adalimumab + Low Dose MethotrexateAdalimumab + High Dose MethotrexateTotal
Female120111231
Male344478
08

Study locations

49 sites
  • Site Reference ID/Investigator# 38982
    Huntsville, Alabama 35801, United States
  • Site Reference ID/Investigator# 38686
    Tuscaloosa, Alabama 35406, United States
  • Site Reference ID/Investigator# 42044
    Mesa, Arizona 85202, United States
  • Site Reference ID/Investigator# 37983
    Phoenix, Arizona 85031, United States
  • Site Reference ID/Investigator# 44823
    Little Rock, Arkansas 72205, United States
  • Site Reference ID/Investigator# 37981
    Hemet, California 92543, United States
  • Site Reference ID/Investigator# 40208
    Long Beach, California 90822, United States
  • Site Reference ID/Investigator# 38423
    Sacramento, California 95816, United States
  • Site Reference ID/Investigator# 38204
    Victorville, California 92395, United States
  • Site Reference ID/Investigator# 40762
    Walnut Creek, California 94598, United States
  • Site Reference ID/Investigator# 43049
    Danbury, Connecticut 06810, United States
  • Site Reference ID/Investigator# 38687
    Jacksonville, Florida 32209, United States
  • Site Reference ID/Investigator# 40105
    Miami, Florida 33169, United States
  • Site Reference ID/Investigator# 38083
    Sarasota, Florida 34239, United States
  • Site Reference ID/Investigator# 38688
    Lawrenceville, Georgia 30045, United States
  • Site Reference ID/Investigator# 38689
    Meridian, Idaho 83642, United States
  • Site Reference ID/Investigator# 38085
    Rock Island, Illinois 61201, United States
  • Site Reference ID/Investigator# 40128
    Springfield, Illinois 62704, United States
  • Site Reference ID/Investigator# 38981
    Bowling Green, Kentucky 42101, United States
  • Site Reference ID/Investigator# 38086
    Covington, Louisiana 70433, United States
  • Site Reference ID/Investigator# 40125
    Fall River, Massachusetts 02720, United States
  • Site Reference ID/Investigator# 65490
    Las Vegas, Nevada 89102, United States
  • Site Reference ID/Investigator# 40124
    Clifton, New Jersey 07012, United States
  • Site Reference ID/Investigator# 38978
    Freehold, New Jersey 07728, United States
  • Site Reference ID/Investigator# 40123
    Voorhees, New Jersey 08043, United States
  • Site Reference ID/Investigator# 38983
    Bronx, New York 10467, United States
  • Site Reference ID/Investigator# 38264
    Smithtown, New York 11787, United States
  • Site Reference ID/Investigator# 38263
    Asheville, North Carolina 28803, United States
  • Site Reference ID/Investigator# 38261
    Greenville, North Carolina 27834, United States
  • Site Reference ID/Investigator# 39024
    Mayfield Village, Ohio 44143, United States
  • Site Reference ID/Investigator# 40127
    Oklahoma City, Oklahoma 73104, United States
  • Site Reference ID/Investigator# 38202
    Bend, Oregon 97701, United States
  • Site Reference ID/Investigator# 39023
    Eugene, Oregon 97401, United States
  • Site Reference ID/Investigator# 38265
    Duncansville, Pennsylvania 16635, United States
  • Site Reference ID/Investigator# 38082
    Jackson, Tennessee 38305, United States
  • Site Reference ID/Investigator# 37980
    Dallas, Texas 75231, United States
  • Site Reference ID/Investigator# 44888
    Dallas, Texas 75246, United States
  • Site Reference ID/Investigator# 43050
    Houston, Texas 77074, United States
  • Site Reference ID/Investigator# 43735
    San Antonio, Texas 78229, United States
  • Site Reference ID/Investigator# 44344
    Richmond, Virginia 23294, United States
  • Site Reference ID/Investigator# 40210
    Seattle, Washington 98101, United States
  • Site Reference ID/Investigator# 38084
    Seattle, Washington 98122, United States
  • Site Reference ID/Investigator# 38542
    Seattle, Washington 98133, United States
  • Site Reference ID/Investigator# 38424
    Spokane, Washington 99204, United States
  • Site Reference ID/Investigator# 38203
    Tacoma, Washington 98405, United States
  • Site Reference ID/Investigator# 38087
    Franklin, Wisconsin 53132, United States
  • Site Reference ID/Investigator# 60850
    San Juan, 00936-5067, Puerto Rico
  • Site Reference ID/Investigator# 38691
    San Juan, 00936-8344, Puerto Rico
  • Site Reference ID/Investigator# 60851
    Vega Baja, 00694-0764, Puerto Rico
09

References and documents

Publications

  • Kaeley GS, MacCarter DK, Pangan AL, Wang X, Kalabic J, Ranganath VK. Clinical Responses and Synovial Vascularity in Obese Rheumatoid Arthritis Patients Treated with Adalimumab and Methotrexate. J Rheumatol. 2018 Dec;45(12):1628-1635. doi: 10.3899/jrheum.171232. Epub 2018 Sep 1. PubMed 30173153 ↗
  • Kaeley GS, MacCarter DK, Goyal JR, Liu S, Chen K, Griffith J, Kupper H, Garg V, Kalabic J. Similar Improvements in Patient-Reported Outcomes Among Rheumatoid Arthritis Patients Treated with Two Different Doses of Methotrexate in Combination with Adalimumab: Results From the MUSICA Trial. Rheumatol Ther. 2018 Jun;5(1):123-134. doi: 10.1007/s40744-018-0105-7. Epub 2018 Mar 24. PubMed 29574622 ↗
  • Burmester GR, Kaeley GS, Kavanaugh AF, Gabay C, MacCarter DK, Nash P, Takeuchi T, Goss SL, Rodila R, Chen K, Kupper H, Kalabic J. Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab. RMD Open. 2017 Sep 17;3(2):e000465. doi: 10.1136/rmdopen-2017-000465. eCollection 2017. PubMed 28955494 ↗
  • Kaeley GS, Nishio MJ, Goyal JR, MacCarter DK, Wells AF, Chen S, Kupper H, Kalabic J. Changes in Ultrasonographic Vascularity Upon Initiation of Adalimumab Combination Therapy in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate. Arthritis Rheumatol. 2016 Nov;68(11):2584-2592. doi: 10.1002/art.39751. Epub 2016 Sep 29. PubMed 27214046 ↗
  • Burmester GR, Landewe R, Genovese MC, Friedman AW, Pfeifer ND, Varothai NA, Lacerda AP. Adalimumab long-term safety: infections, vaccination response and pregnancy outcomes in patients with rheumatoid arthritis. Ann Rheum Dis. 2017 Feb;76(2):414-417. doi: 10.1136/annrheumdis-2016-209322. Epub 2016 Jun 23. PubMed 27338778 ↗
  • Kaeley GS, Evangelisto AM, Nishio MJ, Goss SL, Liu S, Kalabic J, Kupper H. Methotrexate Dosage Reduction Upon Adalimumab Initiation: Clinical and Ultrasonographic Outcomes from the Randomized Noninferiority MUSICA Trial. J Rheumatol. 2016 Aug;43(8):1480-9. doi: 10.3899/jrheum.151009. Epub 2016 Jun 15. PubMed 27307526 ↗

Related links

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2010, a primary completion of Jan 2013 and a completion of Jan 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 18, 2010
First posted
Aug 19, 2010
Start
Sep 2010
Primary completionActual
Jan 2013
CompletionActual
Jan 2013
Results first posted
Mar 18, 2014
Last update
Mar 18, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01185288
Responsible party
Sponsor
First posted
Aug 19, 2010
Start date
Sep 2010
Primary completion
Jan 2013
Completion
Jan 2013
Results posted
Mar 18, 2014
Last update
Mar 18, 2014

Study contacts

Dawn Carlson, MD
study director · AbbVie

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Adalimumab · Methotrexate

Start the discussion